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models that can be used to predict the prognosis 
of patients with advanced HF. The 2 most com‑
monly used scores include the Heart Failure Sur‑
vival Score and the Seattle Heart Failure Model.4 
The first score includes such clinical data as mean 
blood pressure, resting heart rate, left ventric‑
ular ejection fraction, interventricular conduc‑
tion defects, serum sodium levels, mean wedge 
INTRODUCTION Advanced heart failure (HF) 
is one of the most severe cardiovascular disor‑
ders, associated with high incidence, morbid‑
ity, and mortality rates.1 Early identification 
of patients who are at higher risk of poor out‑
come is an important element of patient man‑
agement, both from the medical and economic 
standpoint.2,3 There are several risk stratification 
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ABSTRACT
INTRODUCTION Early identification of patients with advanced heart failure (HF) who are at higher risk 
of poor outcome is an important element of patient management, both from the medical and economic 
standpoint.
OBJECTIVES We sought to determine the association between hematologic parameters assessed on 
admission and within a 3 ‑year follow ‑up in consecutive patients with advanced HF. We also investigated 
the association between baseline demographic and clinical data and mortality.
PATIENTS AND METHODS We analyzed the data of consecutive patients with advanced HF from the single‑
‑center registry COMMIT ‑HF. Patients with hematologic and autoimmune disorders, acute or chronic 
inflammatory diseases, malignant diseases, incomplete clinical and laboratory data, and those receiving 
glucocorticoids were excluded from the study.
RESULTS We analyzed 785 patients with advanced HF out of the total number of 1798 patients included 
in the COMMIT ‑HF registry between 2009 and 2013. The mean (SD) age of the patients was 61.9 (12.4) 
years, and 76.8% of them were male. Diabetes (hazard ratio [HR], 1.46; 95% CI, 1.15–1.86; P = 0.002), 
elevated red blood cell distribution width (RDW; HR, 1.05; 95% CI, 1.04–1.07; P <0.0001), and a low 
relative lymphocyte count (RLC%; HR, 0.942; 95% CI, 0.928–0.956; P <0.0001) were shown to be 
independent predictors of death.
CONCLUSIONS Our study showed that diabetes is a strong independent predictor of death in patients 
with advanced HF. RDW and RLC% are simple, accurate, and widely available markers predicting mortality 
at 3 years in patients with advanced HF.
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HF was diagnosed in cases with confirmed cor‑
onary revascularization procedure or previous 
myocardial infarction. In patients with an un‑
known etiology of HF, coronary angiography was 
performed. Diabetes was diagnosed when one of 
the following criteria was met: 1) diabetes was 
previously diagnosed and documented in the pa‑
tient’s medical records; 2) the patient had a cur‑
rent prescription for oral hypoglycemic medica‑
tion or insulin. The estimated glomerular filtra‑
tion rate was calculated with the Modification 
of Diet in Renal Disease formula; the value of 
less than 60 ml/min/1.73 m2 was diagnostic for 
chronic kidney disease. The definition of anemia 
was based on a report by the World Health Orga‑
nization (hemoglobin levels <12 g/dl for women 
and <13 g/dl for men).7,8
Venous blood samples were collected on ad‑
mission into standardized dipotassium EDTA 
tubes. The samples were tested within 30 minutes 
of collection to minimize variations due to sam‑
ple aging. The complete blood count of patients, 
as well as hematologic parameters such as hemo‑
globin concentration, hematocrit, mean corpus‑
cular volume (MCV), platelet ‑to ‑lymphocyte ra‑
tio (PLR), relative lymphocyte count (RLC%), 
mean platelet volume (MPV), and red blood cell 
distribution width (RDW) were analyzed using 
automated blood cell counters (Sysmex XS1000i 
and XE2100, Sysmex Corporation, Kobe, Japan). 
The intra ‑assay and interassay coefficients of vari‑
ation of the blood samples were 5% and 4.5%, re‑
spectively. RDW was calculated using the follow‑
ing formula: RDW = (SD of red blood cell corpus‑
cular volume) / MCV × 100 [%]. RLC% was calcu‑
lated as the ratio between the lymphocyte count 
and the total white blood cell count. 
During the 3 ‑year follow ‑up, mortality was 
assessed. Data on survival were obtained from 
the national health care provider. Both the regis‑
try and the current study conformed to the Dec‑
laration of Helsinki.
Statistical analysis The statistical analysis was 
performed using the SAS software, version 
9.4 (SAS Institute Inc., Cary, North Carolina, 
United States). Continuous variables were ex‑
pressed as median (25th–75th percentiles), and 
categorical variables—as percentages. Continu‑
ous variables were compared using the Wilcox‑
on–Mann–Whitney test due to nonnormal distri‑
bution, and categorical variables were compared 
using the χ2 test. A univariable Cox proportion‑
al hazards regression analysis was used to select 
the potential independent predictive factors of 
death for inclusion in a multivariable analysis. 
The examined covariables included clinical and 
demographic data (age, sex, obesity, ischemic 
etiology of HF, chronic kidney disease, diabe‑
tes, atrial fibrillation, and hypertension), as well 
as hematologic parameters (PLR, RLC%, RDW, 
MCV, and MPV). The univariable predictors of 
death with a P value of less than 0.1 were entered 
in the multivariable Cox regression model with 
pressure, ischemic etiology of HF, and peak ox‑
ygen consumption. The second score is calculat‑
ed on the basis of 24 variables including com‑
mon clinical parameters obtained at baseline, 
as well as the use of medications and devices. 
Recently, another score has been gaining pop‑
ularity, namely, the Model for End ‑stage Liv‑
er Disease, which is used for the assessment of 
multisystem dysfunction (renal, cardiac, and 
hepatic) and coagulopathy.5
It should be noted, however, that prognostic 
factors in patients with chronic HF are still be‑
ing investigated, because their type and prognos‑
tic value change with time as a result of medical 
progress, as reflected by modifications in man‑
agement standards for patients with HF. Further‑
more, the most useful stratification tools in dai‑
ly clinical practice should include noninvasive, 
simple, repeatable, and readily available tests.
Considering the underlying pathophysiological 
mechanisms of HF, we analyzed the parameters 
reflecting the 2 key processes that affect the de‑
velopment and progression of the disease: neu‑
rohumoral activation and inflammation. These 
are hematologic parameters that can be easily 
measured with modern cell counters used for 
assessing complete blood count. Because com‑
plete blood count is a routine test performed 
in patients with HF, these hematologic indices 
can be used in the assessment of prognosis at no 
additional costs. Therefore, in the present study, 
we sought to determine the association between 
hematologic parameters assessed on admission 
to the hospital and within a 3 ‑year follow ‑up in 
consecutive patients with advanced HF. We also 
investigated the association between baseline 
demographic and clinical data and mortality of 
these patients.
PATIENTS AND METHODS We analyzed the data 
of consecutive patients with advanced chronic 
systolic HF (New York Heart Association [NYHA] 
functional classes III and IV), who were includ‑
ed in a single ‑center registry—COMMIT ‑HF.6 
The registry included 1798 patients with symp‑
tomatic chronic systolic HF (left ventricular ejec‑
tion fraction <35%) who were hospitalized in 
a tertiary referral cardiology center between Jan‑
uary 2009 and December 2013. The exclusion cri‑
teria were age below 18 years and acute coronary 
syndrome as the cause of index hospitalization. 
The current study was a subanalysis of patients 
with advanced HF included in the COMMIT ‑HF 
registry. Patients with hematologic disorders 
(including anemia) and autoimmune disorders, 
acute or chronic inflammatory diseases, malig‑
nancies, incomplete clinical and laboratory data, 
and those receiving glucocorticoids, blood trans‑
fusions, erythropoietin therapy, or intravenous 
iron therapy at the time of enrollment were ex‑
cluded from the study.
HF was diagnosed by the attending physician 
on the basis of guideline recommendations on 
inclusion to the study. The ischemic etiology of 
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stepwise backward elimination. The tolerance 
and variance inflation factor was used to assess 
the correlation between explanatory variables 
and to assess multicollinearity. Schoenfeld re‑
siduals were used to check the proportional haz‑
ards assumption. A P value of less than 0.05 was 
considered significant. The results were present‑
ed as hazard ratios with 95% CIs.
RESULTS We analyzed 785 patients with ad‑
vanced HF out of the total number of 1798 pa‑
tients included in the COMMIT ‑HF registry be‑
tween 2009 and 2013. NYHA class III was report‑
ed for 612 patients, of whom 500 were classified 
as the Interagency Registry for Mechanically As‑
sisted Circulatory Support (INTERMACS) pro‑
file 6, while 112 patients—as INTERMACS pro‑
file 7. There were 173 patients in NYHA class IV, 
of whom 101 were classified as INTERMACS pro‑
file 4 and 72—as INTERMACS profile 5.
Baseline demographic and clinical characteris‑
tics according to the survival or death status are 
presented in TABLE 1. Baseline laboratory charac‑
teristics according to the survival or death sta‑
tus are summarized in TABLE 2. During the 3 ‑year 
follow ‑up, death was reported for 363 patients 
(45%). The multivariable Cox regression anal‑
ysis confirmed that RDW, RLC%, and diabetes 
were significant independent predictors of death 
(TABLE 3). Data on pharmacotherapy at baseline ac‑
cording to the survival or death status are sum‑
marized in TABLE 4.
DISCUSSION The main finding of our study on 
this large unselected population of hospitalized 
patients with advanced HF is that the 2 hemato‑
logic parameters—RDW and RLC%—are associ‑
ated with all ‑cause mortality during the 3 ‑year 
follow ‑up. Moreover, our data support prior find‑
ings on the association between diabetes and 
an increased risk of death during a long ‑term 
follow ‑up.
In accordance with previous reports, we ob‑
served that RDW—a numerical measure of 
the variability in the size of circulating eryth‑
rocytes (anisocytosis)—independently predict‑
ed mortality in patients with chronic HF.9-12 
The exact mechanisms underlying the associ‑
ation between RDW and mortality observed 
in our study remain unknown. It is postulated 
that inflammation may explain the relation‑
ship between a higher RDW and a poorer prog‑
nosis in patients with HF. It is also well docu‑
mented that the inflammatory response plays 
an important role in the development of HF.13 
On the other hand, it is known that inflamma‑
tion inhibits erythrocyte maturation and accel‑
erates the migration of reticulocytes into the pe‑
ripheral circulation, thereby increasing RDW.14 
Forhecz et al12 documented a positive relation‑
ship between RDW and inflammatory indices, 
and observed that higher RDW values were as‑
sociated with significantly lower serum iron and 
ferritin levels. Additionally, they showed that 
TABLE 1 Baseline characteristics of the study groups according to the survival or 
death status
Parameter Survival  
(n = 422)
Death  
(n = 363)
P value
Age, y, median (IQR) 60.9 (52.8–69.4) 63.1 (55.6–74.7) <0.001a
Male sex, n (%) 312 (73.9) 291 (80.2) 0.04b
Chronic kidney disease, n (%) 126 (29.9) 153 (42.1) <0.001b
Diabetes, n (%) 170 (40.3) 197 (54.3) <0.001b
Ischemic etiology of HF, n (%) 262 (62.1) 249 (68.6) 0.05b
ICD/CRT ‑D, n (%) 316 (74.9) 222 (61.2) <0.001b
Arterial hypertension, n (%) 235 (56.04) 182 (50.4) 0.12b
Atrial fibrillation, n (%) 120 (28.6) 135 (37.4) 0.009b
LVDD, mm, median (IQR) 64.5 (59.0–70.0) 63.0 (58.0–70.5) 0.19a
RV, mm, median (IQR) 31.0 (28.0–34.0) 30.0 (28.0 – 34.0) 0.29a
LA, mm, median (IQR) 45.0 (41.0–50.0) 45.0 (40.0–50.0) 0.72a
LVEF, %, median (IQR) 26.0 (21.0–30.0) 27.0 (21.0–31.0) 0.18a
MVR (%) 119 (28.2) 108 (29.8) 0.63b
a Wilcoxon ‑Mann ‑Whitney test;   b χ2 test
Abbreviations: ICD/CRT ‑D, implantable cardioverter–defibrillator/cardiac 
resynchronization therapy device; HF, heart failure; IQR, interquartile range; LA, left 
atrium; LVDD, left ventricular diastolic diameter; LVEF, left ventricular ejection fraction; 
MVR, mitral valve regurgitation; RV, right ventricle
TABLE 2 Baseline laboratory parameters in the study groups according to the 
survival or death status according to the survival or death status
Parameter Survival 
(n = 422)
Death 
 (n = 363)
P vaule*
Leukocytes, 103/mm3 7.5 (6.1–9.1) 7.4 (6.0–9.11) 0.43
Hemoglobin, mmol/l 8.8 (8.0–9.4) 8.7 (8.0–9.3) 0.44
Bilirubin, µmol/l 13.0 (9.3–20.4) 15.3 (9.3–26.3) 0.02
Creatinine, µmol/l 91.0 (75.7–111.2) 101.5 (80.0–128.2) <0.001
Uric acid, µmol/l 421.6 (341.0–505.0) 457.3 (364.0–578.8) <0.001
Glucose, mmol/l 5.7 (5.1–6.7) 5.80 (5.2–7.4) 0.02
HbA1c, % 6.4 (6.0–7.1) 6.6 (6.0–7.1) 0.52
Total cholesterol, mmol/l 4.3 (3.6–5.4) 4.00 (3.3–5.2) 0.002
Triglycerides, mmol/l 1.3 (1.00–1.8) 1.2 (0.9–1.6) <0.001
eGFR, ml/min/1,73 m2 73.0 (57.0–89.4) 64.0 (50.00–84.2) <0.001
Sodium, mmol/l 137. (135.0–139.0) 136.3 (133.2–139.0) 0.002
Platelets, 103/mm3 197.0 (161.0–240.0) 215.0 (172.0–259.0) 0.002
Lymphocytes, 103/mm3 25.5 (19.9–31.3) 19.6 (15.1–27.9) <0.001
PLR 92.7 (72.6–120.6) 150.9 (114.5–200.9) <0.001
RLC% 26.9 (21.5–32.7) 19.2 (14.1–26.2) <0.001
MCV, fl 90.6 (87.0–93.4) 90.1 (86.2–93.8) 0.55
RDW, fl 45.2 (42.9–49.1) 48.7 (45.2–53.2) <0.001
MPV, fl 11.1 (10.4–11.6) 11.9 (10.9–12.6) <0.001
NT ‑proBNP, pg/ml 3050.5  
(1518.0–5214.0)
3307.0  
(1772.0–5728.0)
0.03
Data are presented as median (IQR).
Abbreviations: eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin 
A1c; MCV, mean corpuscular volume; MPV, mean platelet volume; NT ‑proBNP, 
N ‑terminal pro ‑B‑type natriuretic peptide; PLR, platelet ‑to ‑lymphocyte ratio; RDW, red 
blood cell distribution width; RLC%, relative lymphocyte count; others, see TABLE 1
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independent of N ‑terminal pro ‑B‑type natriuret‑
ic peptide, which is a prognostic marker in pa‑
tients with HF.9,20 Furthermore, the lifespan of 
red blood cells is approximately 100 days, which 
is much longer than that of natriuretic peptides.21 
Therefore, RDW may be subject to biological vari‑
ation to a lesser extent, which may make its clin‑
ical interpretation much easier than that of the 
standard laboratory parameters evaluated in pa‑
tients with HF.
The current study demonstrated that anoth‑
er hematologic parameter, RLC%, is an indepen‑
dent predictor of mortality in patients with ad‑
vanced HF. Importantly, our results confirm pre‑
vious findings in other populations with HF.22 
Furthermore, RLC% is a component of the Seat‑
tle Heart Failure Model. Several hypotheses ex‑
plain the association of low RLC% with mortal‑
ity in patients with HF. Lymphocytopenia may 
reflect neurohormonal activation and is a mark‑
er of the physiological stress response mediated 
by an increased release of cortisol and catechol‑
amines in HF.22 Cortisol and catecholamines can 
induce lymphocyte apoptosis and downregulate 
lymphocyte proliferation and differentiation.23 
It is well documented that inflammation and im‑
mune activation play a critical role in the develop‑
ment and progression of HF.24 Moreover, a chron‑
ic activation of lymphocytes and monocytes by 
high levels of cytokines is observed in advanced 
HF.25 It has been postulated that during episodes 
of decompensation and systemic congestion, bac‑
terial endotoxin translocation from the gut into 
the circulation may occur.26 Endotoxin levels in‑
crease especially in patients with HF with volume 
overload and low cardiac output.27 Endotoxin in‑
duces cytokine release and lymphocyte apopto‑
sis, which appear to be the main mechanisms im‑
plicated in the pathogenesis of lymphopenia in 
HF.28 Additionally, lymphopenia may predispose 
patients with HF to infections, which are a well‑
‑known cause of death.
Our data support prior analyses that have 
shown the association between diabetes and 
an increased risk of death during long ‑term 
follow ‑up.29-33 The main metabolic abnormali‑
ties in diabetes include hyperglycemia, hyper‑
lipidemia, and inflammation. They stimulate 
the generation of reactive oxygen species, which 
leads to diabetic complications such as diabet‑
ic cardiomyopathy, coronary artery disease, and 
cardiac autonomic neuropathy.34 The latter af‑
fects blood flow in the coronary arteries and al‑
ters the contractile function of the myocardi‑
um. Patients with cardiac autonomic neurop‑
athy were found to have reduced vascular elas‑
ticity and an increased peripheral vascular re‑
sistance due to abnormal sympathetic tone.34 
Therefore, HF complicates the treatment of dia‑
betes by altering the pharmacokinetics of antidi‑
abetic medications. The results of 2 multicenter 
randomized trials—SOLVD29 and CHARM30—
showed that diabetes was an independent pre‑
dictor of all ‑cause mortality in patients with 
an increased RDW is associated with ineffective 
erythropoiesis and a decrease in renal function.12 
Finally, they observed a strong correlation with 
RDW also for markers of nutritional deficiency, 
such as total cholesterol and albumin levels.12
Westenbrink et al15 reported that a higher RDW 
in patients with HF is associated with elevated 
levels of proinflammatory cytokines and C ‑reac‑
tive protein. Inflammatory cytokines may directly 
inhibit erythropoietin ‑induced erythrocyte mat‑
uration, which leads to an increase in RDW.16 It is 
also known that inflammatory cytokines upregu‑
late hepcidin, which regulates iron homeostasis 
by inhibiting iron absorption from the intestine 
and iron release from reticuloendothelial stores.17
Considering the above findings, it could be 
speculated that increased RDW reflects inflam‑
matory changes in erythropoiesis. Moreover, in‑
creased RDW is associated with reduced erythro‑
cyte deformability, which can impair blood flow 
through microcirculation.18 Based on the current 
evidence, it appears that increased RDW may be 
an important marker of poor stem cell mobiliza‑
tion and bone marrow dysfunction in advanced 
HF.15,19 Although the underlying mechanisms of 
bone marrow dysfunction in these patients have 
not bee elucidated, the possible explanation is 
that apoptosis is triggered by proinflammatory 
cytokines and blunted response of hematopoiet‑
ic stem cells to erythropoietin.15 These data sug‑
gest that RDW may be an integrative measure of 
the main pathophysiological processes that oc‑
cur in HF. Additionally, it has been shown to be 
TABLE 3 Results of a multivariable Cox regression analysis
Parameter HR 95% CI P value
Diabetes 1.46 1.15–1.86 0.002
RDW 1.05 1.04–1.07 <0.001
RLC% 0.94 0.93–0.96 <0.001
Abbreviations: HR, hazard ratio; others, see TABLE 2
TABLE 4 Pharmacotherapy at baseline in the study groups according to the survival 
or death status
Medication Survival (n = 422) Death (n = 363) P valuea
B ‑blocker 410 (97.2) 335 (92.3) 0.002
ACEI 313 (74.3) 230 (65.3) 0.006
ARB 40.0 (9.6) 20.0 (5.7) 0.05
Loop diuretic 378 (89.8) 320 (90.4) 0.8
Digitalis 123 (29.4) 117 (33.3) 0.2
Allopurinol 136 (32.6) 144 (41.3) 0.01
Warfarin 162 (38.7) 139 (39.5) 0.8
Oral hypoglycemic drug 120 (28.8) 136 (38.6) 0.004
Insulin 64 (15.4) 74 (21.3) 0.04
Data are presented as the number (percentage) of patients.
a χ2 test
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker
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widely accepted, it is controversial whether these 
cutoff values may be still applied today.
Yet another limitation of the study is that al‑
though patients did not receive blood transfu‑
sions, erythropoietin therapy, or intravenous iron 
therapy at the time of inclusion, the data on po‑
tential iron therapy or the use of erythropoiesis‑
‑stimulating agents during the follow ‑up peri‑
od are lacking.
A relatively small percentage of patients with 
an implantable cardioverter–defibrillator (ICD) or 
cardiac resynchronization therapy device (CRT ‑D) 
may be explained by the fact that the COMMIT‑
‑HF registry included patients who were hospital‑
ized in our institution for the first time. The rea‑
son for hospitalization was decompensation of 
HF, requiring optimization of pharmacotherapy 
or coronary revascularization before implanta‑
tion. This group also included patients who were 
scheduled to be admitted to our center for ICD 
or CRT ‑D implantation.
In conclusion, RDW and RLC% are simple, ac‑
curate, and widely available markers that predict 
mortality in patients with advanced HF during 
a 3 ‑year follow ‑up. Because complete blood count 
is a routine test for patients with HF, and RDW 
and RLC% are standard hematologic parameters, 
they may be included in a standard assessment 
of prognosis in patients with HF at no additional 
cost. Finally, the present study showed that type 
2 diabetes is a strong independent predictor of 
death in patients with advanced HF.
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